|
From amino acid sequence to bioactivity: The biomedical potential of antitumor peptides
|
22 September 2016 |
|
Cancer treatment using peptides: current therapies and future prospects
|
21 September 2016 |
|
Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors
|
19 September 2016 |
|
Biotherapy of pancreatic neuroendocrine tumors using somatostatin analogs
|
19 September 2016 |
|
HIGHLY INCREASED 125I-JR11 ANTAGONIST BINDING IN VITRO REVEALS NOVEL INDICATIONS FOR SST2 TARGETING IN HUMAN CANCERS
|
13 September 2016 |
|
Melatonin, an inhibitory agent in breast cancer
|
13 September 2016 |
|
ATRA mechanically reprograms pancreatic stellate cells to suppress matrix remodelling and inhibit cancer cell invasion
|
09 September 2016 |
|
Quantitative proteomic profiling reveals that diverse metabolic pathways are influenced by melatonin in an in vivo model of ovarian carcinoma
|
09 September 2016 |
|
Melatonin inhibits tumorigenicity of glioblastoma stem-like cells via the AKT-EZH2-STAT3 signaling axis
|
07 September 2016 |
|
Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer
|
07 September 2016 |